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Abstract
Background: Sulfamethoxazole-trimethoprim (SMX/TMP) is a standard drug for the prophylaxis of Pneumocystis
pneumonia (PJP) in immunosuppressed patients with systemic rheumatic diseases, but is sometimes discontinued
due to adverse events (AEs). The objective of this non-blinded, randomized, 52-week non-inferiority trial was to
quest an effective chemoprophylaxis regimen for PJP with a low drug discontinuation rate. Results at week 24
were reported.
Methods: Adult patients with systemic rheumatic diseases who started prednisolone ≥0.6 mg/kg/day were
randomized into three dosage groups: a single-strength group (SS, SMX/TMP of 400/80 mg daily), half-strength
group (HS, 200/40 mg daily), and escalation group (ES, started with 40/8 mg daily, increasing incrementally to
200/40 mg daily). The primary endpoint was non-incidence rates (non-IR) of PJP at week 24.
Results: Of 183 patients randomly allocated at a 1:1:1 ratio into the three groups, 58 patients in SS, 59 in HS, and
55 in ES started SMX/TMP. A total of 172 patients were included in the analysis. No cases of PJP were reported up
to week 24. Estimated non-IR of PJP in patients who received daily SMX/TMP of 200/40 mg, either starting at this
dose or increasing incrementally, was 96.8–100% using the exact confidence interval as a post-hoc analysis. The
overall discontinuation rate was significantly lower with HS compared to SS (p = 0.007). The discontinuation rates due to
AEs were significantly lower with HS (p = 0.006) and ES (p = 0.004) compared to SS. The IR of AEs requiring reduction in
the dose of SMX/TMP (p = 0.009) and AEs of special interest (p = 0.003) were different among the three groups with
significantly higher IR in SS compared to HS and ES.
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Conclusions: Although there were no PJP cases, the combined group of HS and ES had an excellent estimated
non-IR of PJP and both were superior in safety to SS. From the perspective of feasibility and drug discontinuation
rates, the daily half-strength regimen was suggested to be optimal for prophylaxis of PJP in patients with
systemic rheumatic diseases.
Trial registration: The University Hospital Medical Information Network Clinical Trials Registry number is
UMIN000007727, registered 10 April 2012.
Keywords: Pneumocystis pneumonia, Sulfamethoxazole-trimethoprim, Prophylaxis, Efficacy, Safety, Drug
discontinuation rate, Rheumatic disease, Randomized controlled trial
Background
Pneumocystis pneumonia (PJP, also known as PCP) is a
potentially life-threatening opportunistic infection caused
by Pneumocystis jirovecii [1, 2]. It has a predilection for
immunocompromised patients. In the absence of chemical
prophylaxis, the incidence of PJP is more than 50% in hu-
man immunodeficiency virus (HIV)-positive patients [3],
22–45% in patients with hematological malignancy
[4, 5], and 5–10% in post-organ transplantation pa-
tients [4, 6–8]. In rheumatic diseases, the overall in-
cidence is around 2% [9, 10]; however, the risk is
increased by the use of moderate to high doses of
corticosteroids and concomitant immunosuppressive
drugs and by demographic characteristics and comor-
bidities of patients [11–14].
It is also known that morbidity differs according to
underlying rheumatic diseases: 8–12% in granulomatosis
with polyangiitis, 6.5% in polyarteritis nodosa, 2.7% in
polymyositis/dermatomyositis, 2% in systemic lupus ery-
thematosus, and 0.1–0.3% in rheumatoid arthritis [15].
From the results of post-marketing surveillance pro-
grams for tumor necrosis factor inhibitors in patients
with rheumatoid arthritis in Japan, the incidence rates of
PJP were higher compared to those in the USA [16–18].
In patients who started corticosteroids, conventional im-
munosuppressants or biologics for active rheumatic dis-
eases, PJP is reported to be the second most frequent
pulmonary infection after bacterial pneumonia [19]. It is
also reported that when HIV-negative patients develop
PJP, the onset is more abrupt and mortality is higher
compared to that in HIV-positive patients [1, 20, 21].
The most common and effective prophylactic
method against PJP is the oral administration of low-
dose sulfamethoxazole-trimethoprim (SMX/TMP)
[22, 23]. SMX-TMP consists of two components,
SMX and TMP, both of which inhibit different en-
zymes in the folate synthetic pathway of Pneumocystis
[24]. In HIV-positive patients the prevention rate has
been reported to be 89–100% [25–28] if taken prop-
erly. Despite the high efficacy of SMX/TMP, clini-
cians often have to stop or reduce the dose of the
drug due to adverse events (AEs) such as gastrointes-
tinal symptoms, rash, increased serum creatinine,
renal tubular acidosis, elevation of liver enzymes,
hypoglycemia, hyperpotassemia, and hyponatremia
[29–31]. As a second line drug, pentamidine isethion-
ate, dapsone, or atovaquone is sometimes used, but
these drugs are inferior to SMX/TMP in prophylactic
effect [22, 32]. Because patients with rheumatic dis-
eases are frequently in need of long-term or some-
times lifelong immunosuppressive therapy, it would
be very helpful to have an effective chemoprophylaxis
regimen with a high drug retention rate.
Takenaka et al. [33] conducted a retrospective study to
compare the effectiveness and safety of the conventional
regimen (one daily single-strength tablet of SMX/TMP,
400 mg/80 mg) and the dose escalation regimen (started
with the 10% dose of one single-strength tablet and in-
creased the dose by 10% per week). They reported that
there was no significant difference in the prophylactic ef-
fect on PJP; however, the drug retention rate of the dose
escalation regimen group was better than that of the
conventional regimen group. There is also a systematic
literature review and meta-analysis involving 1245 non-
HIV adults and children with hematologic malignan-
cies, bone marrow transplants, or organ transplants. No
differences in the efficacy between one daily double-
strength (DS) tablet and one DS tablet thrice a week
were reported [28]. Despite these efforts, the optimal
dose and regimen for prophylaxis of PJP in HIV-
negative patients is yet to be determined.
We hypothesized that SMX/TMP of 200 mg/40 mg
with dose escalation had a better drug retention rate and
consequently a better prevention rate than SMX/TMP
of daily 400 mg/80 mg. Considering a cumbersome pre-
scription of the drug with dose escalation, we also set up
an arm of SMX/TMP of 200 mg/40 mg without dose es-
calation. We conducted an open, randomized controlled
trial (RCT) for 52 weeks involving 183 patients with sys-
temic rheumatic diseases starting prednisolone ≥0.6 mg/
kg/day to compare the efficacy, safety, and treatment
discontinuation rates of the three regimens. Here, we
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report the results of the interim analysis of this study up
to week 24.
Methods
Patients
This study was implemented in five university hospitals
and 10 referral hospitals in Japan. Patients were eligible
for enrollment if they fulfilled all the following criteria:
(1) being 20 years of age or older; (2) being admitted to
one of the participating institutions for treatment of
new-onset or relapsed systemic rheumatic diseases in
the period from 30 March 2012 to 28 february 2015; (3)
giving written informed consent; (4) starting 0.6 mg/kg/
day or more of oral prednisolone or equivalent doses of
corticosteroids regardless of concomitant immunosup-
pressive drugs; (5) having not used SMX/TMP, pent-
amidine isethionate, or dapsone previously; and (6)
having serum creatinine within the upper limit of the
normal range of the institution. Major exclusion criteria
were: (1) withdrawing consent; (2) having contraindica-
tions to SMX/TMP; (3) using biologic agents; (4)
having a history of PJP; (5) having uncontrollable com-
plications; (6) having body weight below 40 kg; (7)
being pregnant or a nursing woman; (8) planning to
be pregnant within 24 weeks; and/or (9) being unable
to start SMX/TMP within 10 days of starting
prednisolone.
Study design
This study is a multicenter, open RCT. We performed
computer-based, central, dynamic allocation by using
block randomization. When attending physicians regis-
tered patients to the website, they were automatically
randomly allocated by computer into the single-strength
dosage group (SS), the half-strength dosage group (HS),
or the escalation dosage group (ES), at the ratio of 1:1:1.
All patients were prescribed SMX/TMP in granule form.
Patients in SS started SMX/TMP at the dose of a single-
strength tablet (400 mg/80 mg) and continued the same
dose for 24 weeks. Patients in HS started SMX/TMP at
the half-dose of a single-strength tablet (200 mg/40 mg)
and continued the same dose for 24 weeks. Patients in
ES started SMX/TMP at 10% of the dose of a single-
strength tablet (40 mg/8 mg), and the dose was in-
creased by 10% weekly up to the half-dose of a single-
strength tablet (200 mg/40 mg) and was continued up to
week 24. If SMX/TMP was discontinued before week 24
due to any reason, onward prophylaxis was at the discre-
tion of attending physicians.
After week 24, the use of SMX/TMP including doses
and intervals, and treatment duration were determined
by the attending physician. The observation period was
up to week 52 irrespective of continuation/discontinu-
ation of SMX/TMP unless a patient met the exclusion
criteria. With regard to the protocol, as described in
“Statistical analyses”, we increased the number of cases
because the number of participants meeting the exclusion
criteria was greater than expected. There was no change
in eligibility criteria during the trial. This study was ap-
proved by the ethics committee of the Tokyo Medical and
Dental University Hospital (TMDU) (#2349) and those of
the participating institutions (Additional file 1: Table S1).
This study was registered with the University Hospital
Medical Information Network Clinical Trials Registry
(UMIN000007727).
Endpoints and objectives
The primary endpoint was the non-incidence rate of PJP
(i.e., prevention rate) at week 24. Secondary endpoints
were the following: PJP non-incidence rate at week 52,
treatment discontinuation rate, and AEs. The primary
objective of this study was to show non-inferiority of ES
to SS in terms of non-incidence rates of PJP at week 24.
No patients developed PJP by week 24; thus, we esti-
mated the non-incidence rates of PJP using the exact
confidence interval [33] as a post-hoc analysis. The sec-
ondary objectives were to compare PJP non-incidence
rates between HS and SS, and drug retention rates and
safety among the three groups.
If cases of PJP, suspected PJP, or serious AEs were re-
ported, a clinical event review committee would be
convened according to the study protocol. It comprised
three physicians and included experts in pulmonary
medicine, infectious diseases, and rheumatology. Valid-
ation of PJP as an endpoint was planned to be per-
formed by the clinical event review committee.
Statistical analyses
The full analysis set (FAS) of patients in this study were
those who were enrolled in this study, met the inclusion
criteria, did not meet the exclusion criteria, received at
least one dose of SMX/TMP as a study drug, and had at
least one follow-up visit after starting the drug. We used
the FAS of the patients to analyze efficacy, safety, and
treatment discontinuation rates. An intention-to-treat
analysis was used for assessment of efficacy.
With respect to sample size, we assumed the PJP
non-incidence rate in SS to be 93% and that in ES to be
98%, assuming that a lower discontinuation rate in the
latter would result in better efficacy [23, 33]. We set a
non-inferiority limit of 5%, one-sided α of 0.05, and β
of 0.20. Assuming a percentage of patients who were
randomized but did not meet the aforementioned cri-
teria of FAS (i.e., FAS exclusion) as 5%, we calculated
the sample size to be 55 for each group and a total of
165 patients. However, at one year after the start of the
enrollment, the percentage for FAS exclusion was
found to be more than 5%. We recalculated the sample
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size assuming the percentage to be 10%, and enrolled
58 patients in each group, giving a total of 174
patients.
For statistical analysis we used SPSS (ver.20). Data in
accordance with the normal distribution were assessed
by the mean value ± standard deviation, and data that
did not conform to the normal distribution were
assessed by the median and interquartile range. With
regard to primary outcome, we interpreted that non-
inferiority will be proved if the lower limit of the 95%
confidence interval of the difference between SS and ES
was greater than -5%. For secondary outcomes, we used
Kaplan-Meier methods and the log-rank test to analyze
non-incidence rates and treatment discontinuation rates,
and Fisher’s exact test with adjusted residuals to analyze
the incidence of AEs. If a patient stopped taking SMX/
TMP and restarted the drug within one week, we
deemed the treatment as being continued. The protocol
of this trial will be provided on request.
Results
Randomization and follow-up
The patient disposition is shown in Fig. 1. One-
hundred and eighty-three patients were randomized
into SS (n = 62), HS (n = 61), or ES (n = 60). Four pa-
tients in SS, two in HS, and five in ES were found to be in-
eligible after randomization and were excluded: 58
patients in SS, 59 in HS, and 55 in ES started treatment
with SMX/TMP and met the definition of the FAS. Two
patients in SS, two in HS, and three in ES discontinued
the study because of transfer to another hospital or
death. There were 24 patients in SS, 11 in HS, and 14
in ES who stopped or reduced the dosages of SMX/
TMP due to AEs, prescription errors, or at the discre-
tion of the attending physician (Fig. 1). All patients ex-
cept those who died or were transferred to other
hospitals were followed for 24 weeks.
Baseline characteristics of the patients
Baseline characteristics of the FAS of the patients are
shown in Table 1. The average age was around 60 years
in each group. The proportion of the patients with
underlying polymyositis or dermatomyositis in HS and
of patients with vasculitis syndrome in SS was slightly
higher. Median duration of underlying disease was 2–4
months. The proportion of the patients with interstitial
lung disease as a comorbidity was almost the same
across all groups, except for other lung diseases in SS
and diabetes mellitus in ES, which were slightly higher
than in the others.
Corticosteroids were used before enrollment by 13.3–
15.5% of patients and the dose of prednisolone was
0.94–0.97 mg/kg/day when starting SMX/TMP across
all three groups. Prednisolone dose at week 24 was
around 10 mg/day in each group. The proportions of pa-
tients who used methylprednisolone pulse therapy be-
tween weeks 0 and 12 and those of patients who used
immunosuppressive drugs between weeks 0–12 and weeks
12–24 were slightly different among the three groups.
Enrolled
(n = 183)
Randomization
SS
(n = 62)
ES
(n = 60)
HS
(n = 61)
SS
(n = 58)
Escalation
(n = 55)
HS
(n = 59)
Excluded
(n = 4)
Excluded
(n = 2)
Per
protocol
(n = 32)
Protocol 
deviation
(n = 24)
-AE 
(n = 24)
D/C 
(n = 2)
-Death 
(n = 2)
Per
protocol
(n = 46)
Protocol 
deviation
(n = 11)
-AE 
(n = 11)
D/C 
(n = 2)
-Death 
(n = 2)
Per
protocol
(n = 38)
Protocol 
deviation
(n = 14)
-AE (n = 10)
-Prescription 
error (n = 3)
-Dr.’s decision 
(n = 1)
D/C 
(n = 3)
-Transfer 
(n = 2)
-Death 
(n = 1)
Excluded
(n = 5)
Fig. 1 Randomization and follow-up. There were 183 patients randomized into the single-strength sulfamethoxazole-trimethoprim (SMX/TMP)
dosage group (SS) (n = 62), half-strength dosage group (HS) (n = 61), and the escalation dosage group (ES) (n = 60). There were 4 patients in SS, 2
in HS, and 5 in ES who were found to be ineligible after randomization and were excluded. There were 58 patients in SS, 59 in HS, and 55 in ES
who started treatment with SMX/TMP and met the definition of the full analysis set (FAS). Of these, in SS, HS, and ES, respectively, 2, 2, and 3 pa-
tients discontinued this study because of transfer to another hospital or death, and 24, 11, and 14 patients stopped or reduced SMX/TMP because
of adverse events (AE), prescription error, or on the decision of the attending physician. D/C discontinued
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Table 1 Patient characteristics
SS
(n = 58)
HS
(n = 59)
ES
(n = 55)
Age, years 58.5 ± 15.0 58.1 ± 15.9 60.1 ± 14.4
Female, % 63.8 64.4 70.9
Body weight, kg 55.9 ± 11.8 56.8 ± 10.9 54.5 ± 9.9
Diagnosis
RA, % 8.6 6.8 7.3
SLE, % 10.3 11.9 10.9
PM/DM, % 19.0 37.3 29.1
Vasculitis syndrome, % 44.8 25.4 30.9
Othersa, % 17.2 18.6 21.8
Disease duration, months (IQR) 2 (1–5) 3 (2–7) 4 (2–9)
Comorbidities, % 72.4 79.7 78.2
ILD, % 38.0 44.1 43.6
Other lung comorbiditiesb, % 12.1 8.5 5.5
Hypertension, % 13.8 18.6 14.5
Diabetes, % 6.9 5.1 14.5
CVDc, % 3.4 5.1 5.5
CKD, % 1.7 0 0
Malignancies, % 6.9 11.9 9.1
Others, % 41.4 42.3 36.4
Baseline laboratory data
WBC, /μL (NR, 3300 8600) 10401 ± 5359 9901 ± 4767 9743 ± 5177
Lymphocyte, /μL 1766 ± 1106 1933 ± 1244 1656 ± 877
IgG, mg/dL (NR, 861 1747) 1676 ± 677 1668 ± 679 2006 ± 1945
Treatment before enrollmentd
CS, % 15.5 13.3 14.5
Dosage of CSe, mg/day (IQR) 13.8 (5–15) 8.8 (5–10.6) 6.8 (5–8.125)
ISf, % 1.7 3.2 7.3
Biologics, % 1.7 0 0
Dosage of concomitant CS
At baseline, mg/kg/day (IQR) 0.97 (0.89–1.01) 0.97 (0.81–1.02) 0.94 (0.75–1.05)
At week 24, mg/day (IQR) 12.5 (10–14.25) 11 (9–15) 10 (9–12.5)
Other immunosuppressive treatment between
weeks 0 and 12
IV pulsed mPSL, % 20.6 32.2 20
IS, % 70.6 67.8 81.8
Biologics, % 1.7 3.4 1.8
Other immunosuppressive treatment between
weeks 12 and 24
IV pulsed mPSL, % 1.7 3.4 0
IS, % 65.5 72.9 78.2
Biologics, % 1.7 1.7 3.6
Values that conform to the normal distribution are expressed as the mean ± SD. Values that do not conform to the normal distribution are expressed as the
median (interquartile range). aOthers include systemic sclerosis, mixed connective tissue diseases, Sjogren’s syndrome, adult-onset Still’s disease, relapsing poly-
chondritis, IgG4-related disease, and antiphospholipid syndrome. bOther lung comorbidities include chronic obstructive lung disease, bronchiectasis, bronchial
asthma, pulmonary hypertension, and old tuberculosis. cCardiovascular diseases include cerebral infarction, cerebral hemorrhage, myocardial infarction, and angina
pectoris. dTreatment between 84 days and 1 day before starting or intensifying immunosuppressive treatment. ePrednisolone equivalent dose. fImmunosuppres-
sive drugs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, mizoribine, and mycophenolate mofetil, and tacrolimus. SS the single-strength
dosage group, HS the half-strength dosage group, ES the escalation dosage group, RA rheumatoid arthritis, SLE systemic lupus erythematosus, PM polymyositis,
DM dermatomyositis, IQR interquartile range, ILD interstitial lung disease, CVD cardiovascular disease, CKD chronic kidney disease, WBC white blood cell, NR normal
range, CS corticosteroids, mPSL methylpredonisolone, IS immunosuppressive drugs, IV intravenous
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Efficacy and drug discontinuation rate
Although the primary objective of this study was to
compare the non-incidence rates of PJP at week 24 in SS
and ES, no cases of PJP were reported up to week 24 in
any group. As a post-hoc analysis, we estimated the
non-incidence rates of PJP using the exact confidence
interval [34]. The estimated non-incidence rates in SS,
HS, and ES were 93.8–100%, 93.9–100%, and 93.5–
100%, respectively. Because the patients in HS and ES
received doses of SMX/TMP at 200 mg/40 mg daily
over 24 weeks and 19 weeks, respectively, we combined
these two groups and the estimated non-incidence rate
of PJP was 96.8–100% (n = 114). Estimation using the
rule of three essentially produced the same results [35, 36].
Figure 2a shows the cumulative discontinuation rates
due to any reason, using Kaplan-Meier curves. A signifi-
cant difference was observed between SS and HS (p =
0.007). The cumulative discontinuation rate in ES was
lower than in SS; however, the difference was not statis-
tically significant after Bonferroni correction. Figure 2b
shows the cumulative discontinuation rates due to AEs.
A significant difference was observed between SS and ES
(p = 0.004), and SS and HS (p = 0.006).
Safety
AEs and the breakdown of different AEs are shown in
Table 2. There was no significant difference in the incidence
rates of all AEs and serious AEs. The proportion of the pa-
tients with AEs who required reduction in the dose of
SMX/TMP (p = 0.009) and of patients with AEs of special
interest (p = 0.003) were significantly different across the
three groups, and were higher in SS than in the other two
groups. The AEs of special interest, thrombocytopenia
and hyponatremia, were observed numerically more fre-
quently in SS. We did not determine the statistical signifi-
cance of differences in the numbers of each AE of special
interest because of the relatively small number of cases.
Discussion
In this study, we compared the non-incidence rates, dis-
continuation rates, and safety among SS, HS, and ES, in
order to determine the optimal dose and regimen of
SMX/TMP as prophylaxis for PJP during the treatment
of systemic rheumatic diseases with prednisolone
≥0.6 mg/kg/day. Because no patients developed PJP by
week 24 in this clinical trial, it was not possible to show
the non-inferiority of ES to SS. Regarding secondary
endpoints, the discontinuation rate was significantly
lower in HS compared to SS, and it was lower in ES
compared to SS, although the difference was not statisti-
cally significant after adjusting for multiple testing in the
latter comparison. The discontinuation rates due to AEs
were significantly lower in HS and ES than in SS. The
incidence of AEs that required reduction in the dose of
Fig. 2 a Discontinuation of treatment due to any reason. b Discontinuation of treatment due to adverse events. Cumulative treatment
discontinuation rates are compared using the log-rank test among groups. Numbers of patients at risk of each group at weeks 0, 4, 8, 12, 16, and 20
are shown. SS the single-strength dosage group, HS the half-strength dosage group, ES the escalation dosage group, LL lower limit, UL upper limit
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SMX/TMP and AEs of special interest were significantly
different among the three groups, and both of these AEs
were observed more frequently in SS than in the other
two groups, with statistical significance.
There were no cases of PJP in this study. It is conceiv-
able that high awareness of PJP prophylaxis in the par-
ticipating facilities influenced the non-incidence rate. In
the 49 patients who could not continue the allocated
treatment with SMX/TMP, only 6 patients through
weeks 0–12, and 10 patients through weeks 12– 24, did
not have PJP prophylaxis at all, and the others had some
form of chemoprophylaxis such as reduced dosage of
SMX/TMP, aerosolized pentamidine isethionate, or ato-
vaquone. The incidence rates of PJP in patients with
rheumatic diseases who did not receive chemoprophy-
laxis is reported to be 7.5–9.0% [23, 28, 37]. These data
may explain why there were no cases of PJP in this clin-
ical trial, at least up to week 24.
We estimated the non-incidence rate of PJP in the
combined HS and ES group (n = 114) as 96.8–100% by
the exact confidence interval. The patients in HS and
ES received doses of SMX/TMP at 200 mg/40 mg daily
for at least 19 weeks, and the estimated non-incidence
rates of PJP were quite similar. Taking these figures into
account, it is plausible that a non-incidence rate of PJP in
114 patients receiving SMX/TMP at a dosage of 200 mg/
40 mg daily could be as high as that of the combined
group, suggesting a clinically meaningful prophylactic
effect of this regimen on PJP.
The treatment discontinuation rate due to any reason
was significantly lower in HS compared to SS. The treat-
ment discontinuation rates due to AEs were significantly
lower in HS and ES compared to SS. The incidence rates
of AEs that required discontinuation of SMX/TMP were
lower in HS (8.5%) and ES (9.1%) compared to SS
(20.7%), although there was no statistically significant
difference. These figures were consistent with the previ-
ously reported SMX/TMP discontinuation rates of 8.5–
17.9% in patients with rheumatic diseases [33, 37]. AEs
that required a reduction in the dose of SMX/TMP
were significantly more frequent in SS compared to the
other groups. These data indicate that SMX/TMP of
200 mg/40 mg daily, starting either at this dose or with
a dose-escalation regimen, is superior in its safety and
drug retention rate compared to SMX/TMP of 400 mg/
80 mg daily. Considering that three patients in ES
Table 2 Adverse events
SS
(n = 58)
HS
(n = 59)
ES
(n = 55)
P value
AE, n (%) (95% CI) 32 (55.2)
(41.5–68.3)
24 (40.7)
(28.1–54.3)
26 (47.3)
(33.7–61.2)
0.300
Serious AEa, n (%) (95% CI) 9 (15.5)
(7.3–27.4)
11 (18.6)
(9.7–30.9)
6 (10.9)
(4.1–22.2)
0.534
AE required dose reduction of SMX/TMP, n (%), (95% CI) 11 (19.0)
(9.9–31.4)
2 (3.4)*
(0.4–11.7)
3 (5.5)*
(1.1–15.1)
0.009
AE required discontinuation of SMX/TMP, n (%), (95% CI) 12 (20.7)
(11.2–33.4)
5 (8.5)
(2.8–18.7)
5 (9.1)
(3.0–20.0)
0.110
AE leading to death, n (%), (95% CI) 1 (1.7)
(0–9.2)
3 (5.1)
(1.1–14.1)
1 (1.8)
(0–9.7)
0.622
AE of special interest, n (%), (95% CI) 26 (44.8)
(31.7–58.5)
12 (20.3)*
(11.0–32.8)
10 (18.2)*
(9.1–30.9)
0.003
Fever, n (%) 2 (3.4) 0 (0.0) 0 (0.0) ND
Rash, n (%) 5 (8.6) 2 (3.4) 1 (1.8) ND
Appetite loss, n (%) 1 (1.7) 0 (0.0) 1 (1.8) ND
Anemia, n (%) 1 (1.7) 1 (1.7) 0 (0.0) ND
Leukocytopenia, n (%) 1 (1.7) 1 (1.7) 0 (0.0) ND
Thrombocytopenia, n (%) 9 (15.5) 4 (6.8) 5 (9.1) ND
Elevated LFT, n (%) 7 (12.1) 6 (10.2) 4 (7.3) ND
Elevated serum creatinine, n (%) 3 (5.2) 1 (1.7) 1 (1.8) ND
Hyponatremia, n (%) 5 (8.6) 1 (1.7) 0 (0.0) ND
Hyperpotassemia, n (%) 3 (5.2) 3 (5.1) 1 (1.8) ND
aSerious adverse events (AE): sepsis, organizing pneumonia, severe liver failure, flare of rheumatic disease, rash that required hospitalization, thrombocytopenia
that required hospitalization, mental disorder that required hospitalization, and death. SS the single-strength dosage group, HS the half-strength dosage group, ES
the escalation dosage group, AE adverse events, SMX/TMP sulfamethoxazole-trimethoprim, LFT liver function test, ND not done. *p < 0.05 by adjusted residuals
vs. SS
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discontinued the allocated treatment of SMX/TMP by
prescription errors, the cumbersome regimen of ES ap-
peared to be less feasible than the simple regimen of
HS in clinical practice.
This study has some limitations. First, there was the
possibility of bias from the participating institutions. All
institutions were specialized in rheumatic diseases, had a
high awareness of PJP prophylaxis, and carried out PJP
preventive measures more properly than expected when
the allocated treatment of SMX/TMP was discontinued.
Second, because this was non-blinded study, there
might be a detection bias. Doctors could have an expect-
ation that there might be more AEs in SS due to the
higher dosage. In ES, the necessity of increasing the dos-
age might affect the incidence of AEs, considering more
opportunities to check the condition of the patient com-
pared to a fixed-dose regimen.
Third, the study period for this interim analysis was
only 24 weeks. In the report of 116 HIV-negative
patients, the median duration from the initiation of cor-
ticosteroids to PJP onset has been reported to be
12 weeks [20], and 25% of them developed PJP after
8 weeks or less of corticosteroid treatment. Taking these
data into account, a 24-week observation period for this
analysis would be appropriate. To overcome this limita-
tion, we are continuing this clinical trial up to week 52.
The fourth point is the exclusion criteria of this study.
Patients with decreased renal function or low body
weight may be in need of PJP prophylaxis in a clinical
setting. Because HS was superior to SS in safety, chemo-
prophylaxis with SMX/TMP of 200 mg/40 mg daily may
be applicable to these patients.
Fifth, the variability of the quality of reporting of AEs
and serious AEs should be taken into consideration. To
increase the reliability of the reports, each report was
checked and the research headquarters directed en-
quiries to the attending physician as needed. Finally, this
trial is focused on primary prophylaxis of PJP, and there
is no evidence on the use of SMX/TMP of 200 mg/
40 mg daily as secondary prophylaxis (i.e., prophylaxis
after the first event of PJP) at this time.
Conclusions
This study is the first multicenter RCT comparing the
efficacy, safety, and discontinuation rate of PJP prophy-
laxis using different dosing regimens of SMX/TMP in
systemic rheumatic diseases. Although there were no
cases of PJP in any group, it is estimated that daily or in-
cremental administration of 200 mg/40 mg of SMX/
TMP had a clinically meaningful prophylactic effect on
PJP, had a significantly lower discontinuation rate due to
AEs than the daily single-strength tablet dose of
400 mg/80 mg, and was shown to be superior in safety.
From the perspective of efficacy, safety, and feasibility,
these data suggest that daily SMX/TMP at 200 mg/
40 mg was the optimal regimen for chemoprophylaxis of
PJP in patients with systemic rheumatic diseases. Further
research is required to ascertain data on the efficacy and
safety of PJP prophylaxis using 200 mg/40 mg daily of
SMX/TMP in a clinical setting.
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